Clinical Trial Update: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab to reduce central nervous system side effects after brain radiotherapy in patients with various brain tumors and head/neck …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Anaplastic Ependymoma
• Anaplastic Meningioma
• Brain Stem Glioma
• Ependymoma
• Meningioma
• Oligodendroglioma
• Radiation Toxicity

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Status: COMPLETED | Results posted: 2013-06-14